Printer Friendly

BIOGEN APPOINTS JOSEPH M. DAVIE, PH.D., M.D., AS VICE PRESIDENT-RESEARCH

 CAMBRIDGE, Mass., April 14 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) announced today the appointment of Joseph M. Davie, Ph.D., M.D. as vice president-research. He will be responsible for supervising the company's research programs from discovery through pre- clinical development. He will also serve as a member of Biogen's Scientific Board. Davie joins Biogen from G.D. Searle & Company, Skokie, Ill., where he was most recently corporate senior vice president for science and technology.
 Davie joined Searle in 1987 and served as president of research and development from 1987-1992 and concurrently as senior vice president of preclinical research from 1987-1989. He is an adjunct professor of microbiology and immunology at the schools of medicine at Washington University, St. Louis, and Northwestern University, Chicago.
 Before joining Searle, Davie was associated with Washington University. From 1975-1987, he was professor and chairman of the Department of Microbiology and Immunology at the School of Medicine. Previously, he served as associate professor of pathology and microbiology and director of graduate studies in experimental pathology. From 1969-1972, he was associated with the National Institutes of Health in Bethesda, Md., as a staff associate at the National Institute of Allergy and Infectious Diseases and a resident in pathology at the National Cancer Institute.
 Jim Vincent, Biogen's chairman and chief executive officer, stated, "Joe's appointment marks the conclusion of an intensive search for an individual with skills and accomplishments as both a distinguished scientist and leader in a complex drug development setting. These are the qualities that are critical for us to build on Biogen's scientific excellence and propel us into an exciting commercial future. We feel very strongly that Joe more than satisfies these criteria. In addition, he will add value to the company as a member of our senior management team."
 Davie stated "I am delighted to join one of the world's pre-eminent biotechnology companies, particularly at a time when the opportunities to apply good science to human health have never been greater."
 Davie received a Ph.D. in bacteriology from Indiana University in Bloomington in 1966 and also holds B.A. and M.A. degrees in bacteriology from that institution. He received an M.D. from the Washington University School of Medicine in 1968. Davie is the author of more than 175 publications. He is a member of the Institute of Medicine of the National Academy of Sciences and has served on numerous professional committees and editorial boards.
 Davie, 53, is married and the father of three children. He and his wife will be relocating to the Boston area in the near future.
 Biogen, Inc., headquartered in Cambridge, Mass., is a bioharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and other cancers and viruses.
 -0- 4/14/93
 /CONTACT: (media) Kathryn R. Bloom, director of communications 617-252-9851 or (investors) Amy S. Hedison, director of investor relations, 617-252-9873, both of Biogen/
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER

CH -- NE006 -- 5622 04/14/93 10:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1993
Words:543
Previous Article:HEALTH AND REHABILITATION PROPERTIES TRUST ANNOUNCES QUARTERLY DIVIDEND OF 32 CENTS PER SHARE
Next Article:NEW YORK TELEPHONE INTRODUCES NYNEX ENTERPRISE SERVICES
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY
Biogen Appoints James Green, Ph.D., As Director, Preclinical Development
Names in the News.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters